Report of Foreign Issuer (6-k)
May 15 2018 - 6:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 or 15d-16
UNDER
THE SECURITIES EXCHANGE ACT
of 1934
For the Month of May 2018
001-37521
(Commission File Number)
INTEC PHARMA LTD.
(Translation of registrant’s name into English)
12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel
(+972) (2) 586-4657
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F
☒
Form
40-F
☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________
EXPLANATORY
NOTE
On May 15, 2018, Intec
Pharma Ltd. (the “Company”) announced that its Board of Directors decided to take steps to voluntarily delist the Company’s
ordinary shares from trading on the Tel Aviv Stock Exchange Ltd. (the “TASE”).
Following the delisting
in Israel, the Company’s ordinary shares will continue to trade on the Nasdaq Capital Market (“Nasdaq”) in the
United States and all of its ordinary shares now traded on the TASE are expected to transfer to Nasdaq. Under applicable Israeli
law, including article 35BB of the Israeli Securities Law, the delisting of Company’s ordinary shares from trading on the
TASE will take place three months after the date of this announcement. During the interim period, the Company’s ordinary
shares will continue to be traded on the TASE. The Company will elaborate on subsequent filing the delisting procedures and announce
the exact timeline of its TASE delisting when it becomes available. The Company will continue to file public reports and make public
disclosures in accordance with the rules and regulations of the U.S. Securities and Exchange Commission and Nasdaq.
This report on Form
6-K is incorporated by reference into the Company’s registration statements on Form S-8 (Files No. 333-209700, No. 333-212801
and No. 333-222217).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
INTEC PHARMA LTD.
|
|
|
|
|
|
|
By:
|
/s/
Nir Sassi
|
|
|
|
Name: Nir Sassi
|
|
|
|
Title: Chief Financial Officer
|
Date: May 15, 2018
|
|
|
|
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024